通过依赖m6A的DAPK3降解,YTHDF2促进胆囊癌的进展和耐吉他的抗性
Xuesong Bai1, Jiemin Chen2, Wenqin Zhang2
1Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
RNA结合蛋白YTHDF2通过降解瘤抑制剂DAPK3mRNA来促进胆囊癌 (GBC). 这种机制增强了GBC的进展和耐药性,提供了新的治疗点.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- N6-甲基氨酸 (m6A) 是各种癌症中关键的RNA修饰.
- 在胆囊癌 (GBC) 中m6A及其读者的特定作用尚不清楚.
- YTHDF2是一种m6A读者蛋白,与癌症进展有关.
研究的目的:
- 研究YTHDF2在胆囊癌 (GBC) 的功能和机制.
- 阐明在GBC中由YTHDF2调节的下游目标和途径.
- 探索针对YTHDF2/DAPK3轴用于GBC治疗的潜力.
主要方法:
- 在GBC组织中对YTHDF2表达的定量分析.
- 在体外和体外功能测试以评估YTHDF2的影响2.
- 整合RIP-seq,m6A-RIP-seq和RNA-seq以识别YTHDF2的目标.
- 西方涂抹和光酶测试以验证YTHDF2-DAPK3相互作用.
主要成果:
- YTHDF2在GBC组织中显著上调,并促进GBC细胞的增殖,迁移,入侵和瘤生长.
- YTHDF2的倒退抑制了GBC的进展和亡.
- YTHDF2直接与DAPK3mRNA的3'-UTR结合,以一种m6A依赖的方式促进其降解.
- YTHDF2/DAPK3轴促进了GBC的进展,并赋予了对gemcitabine的耐药性.
结论:
- YTHDF2通过促进DAPK3mRNA降解,在GBC中起到瘤基因的作用.
- YTHDF2 / DAPK3通路对于GBC发育和耐 gemcitabine 耐药性至关重要.
- 针对YTHDF2为GBC提供了一个潜在的治疗策略.
更多相关视频
09:56Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
Published on: April 30, 2019
10:26Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
相关概念视频
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Drugs that Destabilize Microtubules
Abnormal Proliferation
Drugs that Stabilize Microtubules
